Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation by Van den Bossche, Tobi et al.
ARTICLES
Tobi Van den Bossche,
MD
Kristel Sleegers, MD,
PhD
Elise Cuyvers, PhD
Sebastiaan Engelborghs,
MD, PhD
Anne Sieben, MD
Arne De Roeck, MSc
Caroline Van
Cauwenberghe, PhD
Steven Vermeulen, MSc
Marleen Van den Broeck,
BSc
Annelies Laureys, BSc
Karin Peeters, BSc
Maria Mattheijssens, BSc
Mathieu Vandenbulcke,
MD, PhD
Rik Vandenberghe, MD,
PhD
Jean-Jacques Martin,
MD, PhD
Peter P. De Deyn, MD,
PhD
Patrick Cras, MD, PhD
Christine Van
Broeckhoven, PhD,
DSc
On behalf of the Belgian
Neurology Consortium
Correspondence to
Prof. Dr. Van Broeckhoven:
christine.vanbroeckhoven@
molgen.vib-ua.be
Editorial, page 2118
See page 2134
Supplemental data
at Neurology.org
Phenotypic characteristics of Alzheimer
patients carrying an ABCA7 mutation
ABSTRACT
Objective: To generate a clinical and pathologic phenotype of patients carrying rare loss-of-
function mutations inABCA7, identified in a Belgian Alzheimer patient cohort and in an autosomal
dominant family.
Methods:We performed a retrospective review of available data records, medical records, results
of CSF analyses and neuroimaging studies, and neuropathology data.
Results: The mean onset age of the mutation carriers (n5 22) was 73.46 8.4 years with a wide age
range of 36 (54–90) years, which was independent of APOE genotype and cerebrovascular disease.
The mean disease duration was 5.7 6 3.0 years (range 2–12 years). A positive family history was
recorded for 10 carriers (45.5%). All patient carriers except one presented with memory complaints.
The4 autopsied brains showed typical immunohistochemical changes of late-onset Alzheimer disease.
Conclusions: All patients carrying a loss-of-function mutation in ABCA7 exhibited a classical
Alzheimer disease phenotype, though with a striking wide onset age range, suggesting the influ-
ence of unknown modifying factors. Neurology® 2016;86:2126–2133
GLOSSARY
ABCA7 5 ATP-binding cassette subfamily A member 7; AD 5 Alzheimer disease; APP 5 b-amyloid precursor protein; DN 5
dystrophic neurites; GWAS 5 genome-wide association studies; LOF 5 loss of function; MCI 5 mild cognitive impairment;
MoCA 5 The Montreal Cognitive Assessment; NCI 5 neuronal intracytoplasmic inclusions; NFT 5 neurofibrillary tangles;
NT 5 neuritic threads; SP 5 senile plaques.
Alzheimer disease (AD) is the most frequent cause of neurodegenerative dementia.1 Genome-
wide association studies (GWAS) have identified over 20 risk genes that are potentially impli-
cated in AD pathogenesis, though their functional role and significance still has to be fully
elucidated.2–4 In one risk gene, the ATP-binding cassette subfamily A member 7 (ABCA7), rare
loss-of-function (LOF) mutations were reported that were associated with AD in an Icelandic
population, and subsequently replicated in AD cohorts from Finland, Germany, Norway, and
the United States.5 Independently, rare deleterious coding mutations in ABCA7 were identified
in a Caucasian late-onset AD cohort.6
In our Belgian AD cohort, ABCA7 was significantly associated with disease risk and subse-
quent targeted resequencing identified 7 different LOF mutations in ABCA7 in patients with
AD in ABCA7 that were absent in control individuals.7 One frameshift mutation of 7 bp
(p.E709fs), leading to a premature stop codon, cosegregated with disease in an extended auto-
somal dominant AD family, DR170, and was also present in 10 seemingly unrelated patients
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with AD who all shared the same haplotype,
supportive of a genetic relationship to a distant
ancestor. Together, the data indicated that
haploinsufficiency is the underlying cause of
AD in ABCA7 mutation carriers. How this
leads to AD remains unclear, but ABCA7 is
highly expressed in hippocampal microglial
cells and is involved in lipid metabolism, mi-
croglial phagocytosis, and b-amyloid precur-
sor protein (APP) processing.8 Here we report
on the clinical and pathologic characteristics of
the Belgian ABCA7 mutation carriers.
METHODS Study population. The Belgian AD cohort
consisted of 955 patients (65.9% [n 5 629] women, mean
onset age 74.6 6 8.9 years, 50.8% [n 5 485] APOE e41)
selected from a larger prospective memory clinic–based cohort
of Belgian patients with AD.7 All patients received a consensus
diagnosis of possible, probable, or definite AD according to
the National Institute of Neurological and Communicative
Disorders and Stroke–Alzheimer’s Disease and Related
Disorders Association9 or the National Institute on Aging–
Alzheimer’s Association diagnostic criteria.10–12 A positive
familial history (i.e., at least one first-degree relative with an
AD diagnosis) was noted in 15.6% (n 5 149) of patients.
Based on the onset age (#65 years), 16.0% (n 5 124) were
classified as early-onset AD.
A second cohort consisted of 347 Belgian patients with AD
(52.2% [n 5 181] women, mean age at referral 62.6 6 10.0
years, 43.5% [n 5 151] reported familial history) referred to our
molecular diagnostic unit for PSEN1, PSEN2, or APP screening.
Of these, 57.9% (n 5 201) were classified as early-onset AD. All
patients in this cohort were analyzed for mutations in causal AD
genes (i.e., PSEN1, PSEN2, APP) and frontotemporal lobar
degeneration genes (C9Orf72, MAPT, GRN, VCP) as well as
APOE through a MASTR assay or by Sanger sequencing on
genomic DNA.
Standard protocol approvals, registrations, and patient
consents. All participants or their legal guardians signed
informed consent forms for participation in the clinical and
genetic studies. Participants for whom autopsied brain material
was available gave written informed consent for inclusion in path-
ologic studies. All investigations were approved by the Ethics
Committee of the University of Antwerp, the Antwerp University
Hospital, and the Hospital Network Antwerp (ZNA), Belgium.
Molecular genetic analyses. In this study, we genotyped the
p.E709fs mutation in genomic DNA by means of PCR-based
amplification followed by Sanger sequencing as previously
described.7 A panel of polymorphic simple tandem repeat
markers covering the ABCA7 locus, as well as single nucleotide
polymorphism genotype data in the locus, were used as previously
described to examine allele and haplotype sharing among
p.E709fs mutation carriers.7
Clinical analyses. Medical records of ABCA7 mutation carriers
were reviewed. Onset age was defined as onset of the first symp-
tomatology (e.g., memory problems) as reported through history
from the patient or the informant. Disease duration was measured
from symptom onset until death. Structural or functional
neuroimaging was performed and interpreted at the referring
neurologic center. CSF AD biomarkers (Ab1-42, total tau, and
p-tau181P) were determined as previously described.13
Neuropathologic analyses. Available neuropathology data of
ABCA7 mutation carriers was reviewed and autopsied brain
reexamined. After fixation in 10% buffered formalin, brains
were embedded in paraffin. Sections were prepared from the
cingulate gyrus, frontal superior gyrus, temporal superior
gyrus, hippocampus, area striata, mesencephalon, pons, and
cerebellum. Histology was performed using Cresyl violet,
hematoxylin & eosin, Bodian, and Klüver-Barrera. Immuno-
histochemical analysis was performed with Ubiquitin (Dako,
Glostrup, Denmark), AT8 (Innogenetics, Zwijnaarde, Bel-
gium), 4G8 (Signet, Dedham, MA), TDP-43 (Proteintech
Group Inc., Chicago, IL), FUS (Proteintech Group Inc.),
and P62 (BD Diagnostics, Erembodegem, Belgium).
RESULTS We identified 22 patients carrying a LOF
mutation in ABCA7, 18 by sequencing of ABCA7 in
the Belgian AD cohort,7 and 4 in this study by targeted
mutation screening for the founder mutation, p.E709fs,
in a group of patients with AD who were referred for
medical genetic testing (tables 1 and 2 and figure e-1 on
the Neurology® Web site at Neurology.org). Fifteen
patients carried the p.E709fs mutation; the others
Table 1 ABCA7 loss-of-function mutations in Belgian patients with Alzheimer disease
Mutation
No. patients
APOE genotypes, %
Mean 6 SD OA Mean 6 SD DD FH1, %cDNA Protein e3/e3 e3/e4 e4/e4
c.2124_2130del7 p.E709fs 15 0.47 0.40 0.13 73.9 6 8.6 6.8 6 3.0 0.53
c.1621-1622del2 p.V541fs 1 NA 1 NA 73 — 1
c. 3641G>A p.W1214* 1 NA 1 NA 84 4 —
c.4202delA p.Q1401fs 1 1 NA NA 82 2 —
c. 4690C>T p.R1564* 1 NA 1 NA 72 3 —
c.6134insT p.A2045fs 1 NA 1 NA 69 — —
c.67-1G>A p.0 2 0.50 0.50 NA 62.5 6 1.5 4 0.50
All 22 0.41 0.50 0.09 73.4 6 8.4 5.7 6 3.0 0.46
Abbreviations: DD 5 disease duration in years; FH1 5 positive familial history; NA 5 not applicable; OA 5 onset age in
years.
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Table 2 Clinical characteristics of Belgian patients carrying an ABCA7 loss-of-function mutation
Mutation Patient ID Sex
APOE
genotype OA F/S
Presenting
symptom
Structural imaging (CT/MRI)
Functional imaging
(perfusion SPECT) CSF Clinical diagnosis NeuropathologyaAtrophy Other
p.E709fs DR170.1 F 34 72 F Memory Y CT: T (R) . G CML1 PT (R1L) Y — AD A3B3C3
p.E709fs DR73 F 34 66 U Memory Y CT: Sc . Co CML1 FP (L.R), T (R1L) Y — AD A3B2C2-3
p.E709fs DR469 M 33 54 F Memory Y CT: G FP 1 TO (R1L) Y — AD —
p.E709fs DR1087 F 44 74 F Memory Y CT: G CML11 FP (R1L), TO (L) Y — AD —
p.E709fs DR1088 F 33 74 F Memory Y CT: T (L1R) . G AD compatible — AD —
p.E709fs DR400 F 33 74 F Memory Y CT: T (R) . G CML11, ICH PO (R) FP (R1L), T (R), C (L) Y — AD —
p.E709fs DR1090 F 34 85 S Parkinsonism 1 memory Y MRI: G FP (R1L) Y — AD —
p.E709fs DR1091 M 33 79 S Memory Y MRI: G CML11 — ADb AD —
p.E709fs DR1092 F 33 90 S Memory Y CT: Co . Sc, T (R.L) CVA PT (R) PT (R) Y — MXD A3B2C2-3
p.E709fs DR1093 M 33 80 U Memory Y CT: G AD compatible — AD —
p.E709fs DR1094 F 34 83 S Memory Y — — — — AD —
p.E709fs DR1187 F 44 65 F Memory Y — — — — AD —
p.E709fs DR1189 F 34 ,73 F Memory Y — — — — AD —
p.E709fs DR1190 M 33 ,71 F Memory Y — — — — Progressive memory Y —
p.E709fs DR1188 M 34 ,69 U Memory Y — — — — AD —
p.V541fs DR1228 F 34 73 F Memory Y CT: No atrophy HFI PT (R1L) Y — AD —
p.W1214* DR1229 M 34 84 S Memory Y CT: G CML1 PT (R1L) Y — AD A2B2C1-2
p.Q1401fs DR945 M 33 82 U Memory Y MRI: Sc . Co, HC (R1L) CML111 — ADb AD —
p.R1564* DR851 F 34 72 U Memory Y CT: T (R1L) . G CML1 PT (R1L) Y — AD —
p.A2045fs DR1230 F 34 69 U Word retrieval Y 1 memory Y MRI: Co CML1 FP (L), T (L) Y — AD —
c.67-1G>A DR1231 M 33 64 U Memory Y CT: G PO (R1L) Y — AD —
c.67-1G>A DR474 F 34 61 F Memory Y CT: G PO (L) Y — AD —
Abbreviations: Y 5 decreased; — 5 not available; AD 5 Alzheimer disease; C 5 cerebellar; CML 5 chronic microvascular lesions (1 limited, 11 moderate, 111 extensive); Co 5 cortical; CVA 5 cerebrovascular
accident; F/S 5 familial/sporadic; FP 5 frontoparietal; G 5 global; HC 5 hippocampal; HFI 5 hyperostosis frontalis interna; ICH 5 intracerebral hemorrhage; MXD 5 mixed dementia; OA 5 onset age in years; PO 5
parieto-occipital; PT 5 parietotemporal; Sc 5 subcortical; T 5 temporal; U 5 unknown.
aNeuropathologic changes according to Montine et al. (2012).12
bCSF biomarker profile (Ab1-42, total tau, p-tau181P) characteristics.
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carried a nonsense (n 5 2), frameshift (n 5 3), or
splicing mutation (n 5 2).
Clinical characteristics. Mean onset age (n 5 19), or
when not available age at referral (n5 3), was 73.46
8.4 years with a wide range of 36 (54–90) years.
The mean disease duration was 5.76 3.0 years with
a range of 10 (2–12) years. All patients presented
with progressive memory impairment except for
DR1090, who had onset of nonprogressive asym-
metric rigidity in the limbs and a festinated gait,
which responded to low-dose levodopa, 1 year
before onset of memory complaints (table e-1).
Clinical criteria for Lewy body dementia were not
met.14 In 3 other patients (DR170.1, DR400, and
DR1094), mild extrapyramidal signs developed
during the disease course. In DR170.1, a mild
symmetric rigidity was noted in the advanced
dementia stage, whereas DR400 and DR1094
showed mild symmetric extrapyramidal signs after
initiation of antipsychotics. In DR1230, the
onset of memory problems was accompanied by
word-finding difficulties that were the initial
predominant clinical feature. Further progression
of the disease was typical of AD, with memory
impairment dominating the clinical picture.
An extensive neuropsychological examination was
available for 17 patient carriers showing marked
amnesia as well as at least one other affected cognitive
domain. One patient, DR1092, showed a slight
asymmetry in her neurocognitive profile, which, in
combination with the vascular lesions visualized on
brain CT and perfusion SPECT, led to a mixed
dementia diagnosis. In DR945, the neurocognitive
profile showed evidence of both cortical and subcor-
tical dysfunction. Due to the presence of mild visual
hallucinations and delusions, as well as the observa-
tion of slightly fluctuating attention, an initial differ-
ential diagnosis of Lewy body dementia was made.
Frontal signs in the neurocognitive profile were
noted in 7 (7/17, 41.2%) patients, although these
were not the presenting symptom. In addition, clini-
cal observation revealed 13 patients (13/17, 76.5%)
showing signs of disinhibition (n 5 9) or marked
behavioral disturbances (n 5 9) during their disease
course. Frontal release signs at clinical examination
were noted in 4 patients (4/17, 23.5%). Language
difficulties were present in 10 patients (10/17,
58.8%), most notably in the form of word-finding
difficulties (n5 8) or diminished verbal fluency (n5
4). Six patients (6/17, 35.3%) showed marked signs
of depression, with one patient exhibiting a pseudo-
bulbar affect with uncontrollable crying. Delusions
were present in 4 patients (4/17, 23.5%), with 3
patients (3/17, 17.6%) exhibiting paranoid delusions.
Visual hallucinations were present in 3 patients (3/17,
17.6%), although in DR1090 visual impairment due
to advanced bilateral cataract was an important dif-
ferential diagnosis. In 2 patients (2/17, 11.8%), epi-
leptic seizures occurred during the disease course.
DR474 had a generalized seizure, presumed to be
of a neurodegenerative etiology, in the late-stage
dementia phase, whereas in DR400 generalized
seizures occurred secondary to an intracerebral
hemorrhage.
Neuroimaging characteristics. Brain CT protocols were
available for 17 carriers (table 2). In accordance with
disease progression, diffuse (sub)cortical atrophy was
noted, in 3 patients (3/17, 17.6%) more striking in
the (medial) temporal region. Brain MRI was per-
formed in 4 patients, showing diffuse cerebral atrophy
with variable signs of chronic cerebrovascular disease.
In DR945, bilateral hippocampal atrophy was evident
as well (figure e-2). Brain perfusion SPECT was per-
formed in 15 patients and mainly reflected a relative
hypoperfusion in the parietotemporal regions, with
relatively preserved perfusion in the sensorimotor cor-
tex. In 10 patients (10/15, 66.7%), the relative hypo-
perfusion extended to the frontal regions. Of note,
SPECT imaging in DR400 revealed a bilateral fron-
toparietal hypoperfusion, suggestive for a frontal lobe
dementia. In addition, asymmetric hypoperfusion in
the right-sided temporal lobe and the contralateral
cerebellar hemisphere (crossed cerebellar diaschizis),
compatible with an old infarction in the right
temporal lobe as previously visualized on brain CT,
was noted. However, based on the clinical phenotype,
the diagnosis of AD was retained.
CSF analysis. In 2 patients (DR1091 and DR945),
CSF AD biomarker analyses were performed. Both
biomarker profiles were characteristic of AD with
decreased CSF Ab1-42 levels and increased CSF total
tau and p-tau181P levels. This profile is known to have
a high sensitivity and specificity for AD with diagnos-
tic accuracy exceeding 80% in the setting of estab-
lished cognitive impairment.13 Of note, the total tau
level in DR1091 was very high (1,460 pg/mL), with
an increased p-tau181P level of 145.7 pg/mL, but no
clinical features suggestive for recent stroke or
Creutzfeldt-Jakob disease were present.
Neuropathologic characteristics. In 4 patient carriers,
brain autopsy had been performed (table 2 and figure
1). Three patients, DR170.1, DR1092, and DR73,
carried the p.E709fs mutation in ABCA7, whereas
DR1229 carried a p.W1214* mutation. Both muta-
tions lead to a premature stop codon and subsequent
degradation of the mutant transcript by the nonsense-
mediated RNA decay control mechanism.7
Patients DR170.1, DR1092, and DR1229 had cor-
tical atrophy with neuronal loss in CA1, the subiculum,
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and entorhinal cortex, which for DR1229 was also evi-
dent in CA2 and the transentorhinal cortex. In DR73,
severe atrophy with neuronal cell loss was present in the
frontal and temporal cortex, as well as the hippocampus
and parahippocampal structures.
DR170.1 had high amounts of senile plaques (SP)
in the cortex and molecular layer of the cerebellar cor-
tex, with sporadic SP in the reticular formation of the
mesencephalon and pons. In DR73, very large
amounts of SP in the cortex and to a lesser extent
in the cerebellar cortex, mesencephalon, and pons
were present. In DR1092, a maximum of diffuse
and classic SP was found in the cingulate gyrus, fron-
tal superior gyrus, temporal superior gyrus, hippo-
campus, and area striata, while SP in the molecular
cortical layer of the cerebellum and the reticular for-
mation were less in number. DR1229 had a severe
Ab immunoreactivity with diffuse and neuritic SP
in the cortex, cerebellum, and reticular formation of
the mesencephalon and pons. A severe amyloid angi-
opathy was present in DR73 and DR1229, and to a
lesser extent in DR1092, but was absent in DR170.1.
Tau pathology was evident in DR170.1 with small
neurofibrillary tangles (NFT) and neuronal intracyto-
plasmic inclusions (NCI) in the upper cortical layers
and classic NFT in the deeper cortical layers. In
DR1092, typical NFT were also present in the deeper
cortical layers, while in the superficial layers, the neu-
ronal inclusions resembled NCI. Sporadic NFT were
found in the reticular formation of the mesencepha-
lon. In DR73, a large amount of NFT (and NCI-
like) pathology was present in every part of the cortex.
The classical NFT as well as the small NCI-like NFT
in the upper cortical layers also stain with AT8 and
TDP-43. The fused in sarcoma staining was negative.
In DR1229, a moderate amount of NFT, neuritic
threads (NT), and dystrophic neurites (DN) were
found in all examined cortices, more so in the allocor-
tex. The substantia nigra, locus ceruleus, and reticular
formation of the mesencephalon and pons were
mildly affected. TDP-43 showed occasional NCI,
more pronounced in the superficial cortical layers.
NCI were seldom found in the dentate gyrus of the
hippocampus.
ABCA7 p.E709fs founder mutation. In total, we identi-
fied 15 apparently unrelated patients with AD carry-
ing p.E709fs. This mutation segregated in AD family
DR170 with autosomal dominant inheritance (table 3
and figure 2).7 All 14 carriers of p.E709fs, unrelated
to DR170, shared the same disease haplotype that
segregated in family DR170, indicative of a founder
effect of p.E709fs in the Belgian population. All
p.E709fs carriers received a probable (n 5 12) or
definite AD (n 5 3) diagnosis, except for the 3 at-
risk individuals (III-1, III-6, and III-2) of family
DR170, who were diagnosed with subjective or
mild cognitive impairment (MCI). All 3 presently
report memory problems at age 73 (III-1), 78
(III-6), and 74 (III-2) years. For carriers III-1 and
III-6, history and cognitive screening was compatible
with MCI, with an onset age of 71 (III-1) and 75
(III-6) years. The Montreal Cognitive Assessment
(MoCA) showed abnormal results within the MCI
range 19–25 for III-1 (MoCA score of 21/30) and
III-6 (MoCA score of 23/30), who both made
Figure 1 Neuropathology findings in ABCA7 loss-of-function mutation carriers
The 4G8 staining shows extensive amyloid angiopathy in 3 out of 4 patients (A) and extensive amyloid senile plaques (B) in the frontal cortex. Classic neu-
rofibrillary tangles are present in the hippocampal CA1 (C [AT8 stain]). In photographs (D) through (F), the superficial cortical layers of the entorhinal cortex
are shown. Multiple neuronal intracytoplasmic inclusions stain with p62 (D), AT8 (E), and TDP-43 (F).
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mistakes on the Clock Drawing Test and the delayed
recall task. Carrier III-2 scored within the normal
range (MoCA score of 28/30), although she lost 2
points on the delayed recall task and made a
mistake on the Clock Drawing Test, which was
self-corrected. Of note, II-2 and II-4, who are
obligate p.E709fs carriers based on the segregation
data in family DR170, were also diagnosed with
AD with an onset age of 80 (II-2) and 70 (II-4)
years. Three other family members (I-1, II-6, and
III-4) were diagnosed with AD, at age 80 (I-1), 78
(II-6), and 59 (III-4) years. No biosamples were
available and segregation analysis was uninformative
to investigate their p.E709fs carrier status. Family
member III-5, in whom molecular genetic analysis
confirmed the absence of p.E709fs, was diagnosed
with Parkinson disease at age 75 years.
DISCUSSION We provide a detailed clinicopatho-
logic description of patients carrying an ABCA7
LOF mutation. The clinical AD diagnosis in the
patient carriers appears strong, since most exhibited
Table 3 Belgian Alzheimer disease (AD) family DR170 segregating the ABCA7 p.E709fs founder mutation
DR170a family
members Sex Status
Current age/age
at death (†), y
APOE
genotype OA DD Remarks p.E709fs
I-1 M AD 85 (†) — 80 5 — No DNA
II-1 F Definite AD 78 (†) 34 72 6 †Due to massive CVA Yes
II-2 F AD 89 (†) — 80 9 — Obligate carrier
II-4 F AD 83 (†) — 70 13 — Obligate carrier
II-6 M AD 80 (†) — 78 2 — No DNA
III-1 F MCI 73 33 71 — MoCA 21/30; functional status intact Yes
III-2 F SCI 74 33 59 — MoCA 28/30; normal NPE; functional
status intact
Yes
III-4 F AD 70 (†) — 59 11 — No DNA
III-5 M PD 80 (†) 33 75 5 — No
III-6 F MCI 78 33 75 — MoCA 23/30; functional status intact Yes
Abbreviations: CVA 5 cerebrovascular accident; DD 5 disease duration in years; MCI 5 mild cognitive impairment; MoCA 5 Montreal Cognitive Assess-
ment; NPE 5 neuropsychological examination; OA 5 onset age in years; PD 5 Parkinson disease; SCI 5 subjective cognitive impairment.
a The DR170 pedigree is shown in figure 2 with family members numbering per generation.
Figure 2 Alzheimer disease (AD) family DR170 segregating the ABCA7 p.E709fs founder mutation
Dark filled symbols indicate patients with AD, the half-filled symbol indicates mild cognitive impairment (MCI), and the quarter-filled symbol indicates sub-
jective cognitive impairment (SCI). The arrow indicates the proband of family DR170. The 5 individuals for whom we have DNA available are marked by an
asterisk. The open circle indicates a patient with Parkinson disease (PD). AAO 5 age at onset in years.
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a classical AD phenotype with conforming technical
investigations and strict application of diagnostic
criteria.9–12 Almost all patients were seen in a special-
ized memory clinic by neurologists with extensive
experience in cognitive impairment. Moreover,
in all 4 carriers in whom brain autopsy was per-
formed, the clinical AD diagnosis was confirmed
neuropathologically.
However, 4 (18.2%) patients had an initial differ-
ential diagnosis of vascular dementia (DR1092), fron-
totemporal dementia (DR400), or dementia with
Lewy bodies (DR945 and DR1090). In DR1092,
autopsy confirmed the presence of SP and NFT, the
diagnostic hallmark pathologic lesions of AD. In
DR400, an initial differential diagnosis with fronto-
temporal dementia was made, but during further pro-
gression of disease, a diagnosis of AD, with frontal
signs, remained most likely. Some degree of frontal
dysfunction has been known to occur frequently in
the Belgian AD population, with up to 97% of pa-
tients with AD exhibiting at least one frontal lobe
symptom.15 In patients DR945 and DR1090, demen-
tia with Lewy bodies was considered, in part due to the
presence of visual hallucinations, although they were
not markedly present during the clinical evaluation. Of
note, a recent study in a Belgian cohort of patients with
MCI and AD found that psychosis-related symptoms
(such as delusions or hallucinations) were present in up
to 40% of patients with AD.16 In patient DR1090, the
onset of memory problems was also preceded by mild
parkinsonian features, which remained stable during
the disease course under an unchanging dose of
levodopa. A consensus diagnosis of AD was made,
although the possibility of a concomitant Lewy body
pathology could not be excluded.
The progression of disease in ABCA7 LOF patient
carriers (mean disease duration of 5.7 6 3.0 years)
seems to be slightly shorter compared to the complete
Belgian AD patient cohort (6.9 6 3.9 years). How-
ever, clinical significance seems unlikely, and the nor-
mal life expectancy and late onset in most carriers
could have interfered with this observation. However,
the observation of a wide range in onset age (36 years)
does seem clinically significant. When considering
potential modifiers of onset age such as APOE geno-
type and signs of vascular damage on neuroimaging,
we could not provide a clear explanation for this
observation. This could be due to another strong
modifier or the additive effect of different modifiers
with minor effect sizes. For example, patient DR469,
who had an early onset age of 54 years, was previously
shown to also carry 2 rare mutations in the AD
GWAS risk gene clusterin, CLU (p.T445_D447del
and p.A309T), though the functional and biological
significance of these mutations is not fully eluci-
dated.17 Both CLU and ABCA7 have been linked to
lipid metabolism, neuroinflammation, and the amy-
loid cascade and possibly share a pathogenic pathway.
Further investigations are needed to see if an interac-
tion or additive effect of genetic variation in ABCA7
and CLU, or in other AD risk genes, exist and influ-
ence disease phenotype.
Neuropathologic findings were typical of AD,
showing severe amyloid pathology in the hippocam-
pus and cortex. In addition, 3 out of 4 patients
showed a severe amyloid angiopathy although
there were no clear signs thereof on antemortem
neuroimaging. To a lesser extent—although still
severe—tau pathology was present, mainly character-
ized by NFT, NT, and DN, but in the superficial
cortical layers NFT were small and had many simi-
larities with NCI. Interestingly, these NCI have a
tendency to costain with TDP-43. Further investiga-
tions are needed to see if this is a genuine colocaliza-
tion. Of note, TDP-43 immunoreactivity was
reported to occur in up to 57% of patients with AD.18
Based on our findings, the clinicopathologic
findings in ABCA7 LOF mutation carriers seem to
conform with a classical AD phenotype. Notwith-
standing the later onset age in most ABCA7 carriers,
we observed a higher familial load (45.5% with pos-
itive familial history for AD) when compared to the
complete Belgian AD patient cohort (23%). There-
fore, genetic diagnostic testing for ABCA7 mutations
in familial late-onset AD analysis might be consid-
ered, particularly in the context of a founder effect,
as we observed in Belgium. Nonetheless, ABCA7
LOF mutations in AD are rare events with a preva-
lence in the Belgian AD cohort of 1.2% for the
founder mutation and 0.9% for all other pooled
LOF mutations. Consequently, the number of
ABCA7 mutation carriers we described in this study
is low and generalization of the genotype–phenotype
findings should be avoided until additional carriers
have been studied.
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